JP2006510676A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006510676A5 JP2006510676A5 JP2004559435A JP2004559435A JP2006510676A5 JP 2006510676 A5 JP2006510676 A5 JP 2006510676A5 JP 2004559435 A JP2004559435 A JP 2004559435A JP 2004559435 A JP2004559435 A JP 2004559435A JP 2006510676 A5 JP2006510676 A5 JP 2006510676A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- composition according
- composition
- inflammation
- autoimmune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 15
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 claims 5
- 206010003816 Autoimmune disease Diseases 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 3
- 206010012601 Diabetes mellitus Diseases 0.000 claims 3
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 206010001897 Alzheimer's disease Diseases 0.000 claims 2
- 206010002556 Ankylosing spondylitis Diseases 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 208000006673 Asthma Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 206010020243 Hodgkin's disease Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 206010037162 Psoriatic arthropathy Diseases 0.000 claims 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 2
- 208000006641 Skin Disease Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 206010043189 Telangiectasia Diseases 0.000 claims 2
- 208000009056 Telangiectasis Diseases 0.000 claims 2
- 206010047461 Viral infection Diseases 0.000 claims 2
- 208000001756 Virus Disease Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 201000001320 atherosclerosis Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 201000009910 diseases by infectious agent Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 210000000056 organs Anatomy 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 230000001575 pathological Effects 0.000 claims 2
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 claims 2
- 201000004681 psoriasis Diseases 0.000 claims 2
- 201000001263 psoriatic arthritis Diseases 0.000 claims 2
- 200000000008 restenosis Diseases 0.000 claims 2
- 230000037380 skin damage Effects 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 231100001005 telangiectasia Toxicity 0.000 claims 2
- 230000017423 tissue regeneration Effects 0.000 claims 2
- 210000001519 tissues Anatomy 0.000 claims 2
- 230000017613 viral reproduction Effects 0.000 claims 2
- SAYGKHKXGCPTLX-UHFFFAOYSA-N 2-(carbamoylamino)-5-(4-fluorophenyl)thiophene-3-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N)SC(C=2C=CC(F)=CC=2)=C1 SAYGKHKXGCPTLX-UHFFFAOYSA-N 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims 1
- 102000003945 NF-kappa B Human genes 0.000 claims 1
- 108010057466 NF-kappa B Proteins 0.000 claims 1
- 102000030951 Phosphotransferases Human genes 0.000 claims 1
- 108091000081 Phosphotransferases Proteins 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43149602P | 2002-12-06 | 2002-12-06 | |
| PCT/US2003/038970 WO2004053087A2 (en) | 2002-12-06 | 2003-12-05 | Nf-κb inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006510676A JP2006510676A (ja) | 2006-03-30 |
| JP2006510676A5 true JP2006510676A5 (pt-PT) | 2007-05-24 |
Family
ID=32507737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004559435A Pending JP2006510676A (ja) | 2002-12-06 | 2003-12-05 | ＮＦ−κＢ阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20060116419A1 (pt-PT) |
| EP (1) | EP1569924A4 (pt-PT) |
| JP (1) | JP2006510676A (pt-PT) |
| AU (1) | AU2003300832A1 (pt-PT) |
| WO (1) | WO2004053087A2 (pt-PT) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6702949B2 (en) | 1997-10-24 | 2004-03-09 | Microdiffusion, Inc. | Diffuser/emulsifier for aquaculture applications |
| ES2314443T3 (es) | 2003-08-15 | 2009-03-16 | Astrazeneca Ab | Tiofenos sustituidos y sus usos. |
| GB0400895D0 (en) * | 2004-01-15 | 2004-02-18 | Smithkline Beecham Corp | Chemical compounds |
| PE20060373A1 (es) * | 2004-06-24 | 2006-04-29 | Smithkline Beecham Corp | Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2 |
| US8063071B2 (en) * | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
| EP2001455A2 (en) | 2006-03-15 | 2008-12-17 | Theralogics, Inc. | Methods of treating muscular wasting diseases using nf-kb activation inhibitors |
| CA2682189C (en) * | 2006-04-07 | 2015-12-08 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers |
| JP5595041B2 (ja) * | 2006-10-25 | 2014-09-24 | リバルシオ コーポレイション | 酸素富化溶液を用いる、眼および他のヒト組織の治療処置の方法 |
| US8784897B2 (en) | 2006-10-25 | 2014-07-22 | Revalesio Corporation | Methods of therapeutic treatment of eyes |
| US8609148B2 (en) | 2006-10-25 | 2013-12-17 | Revalesio Corporation | Methods of therapeutic treatment of eyes |
| US8784898B2 (en) * | 2006-10-25 | 2014-07-22 | Revalesio Corporation | Methods of wound care and treatment |
| EP3170401B1 (en) | 2006-10-25 | 2019-06-05 | Revalesio Corporation | Ionic aqueous fluid composition containing oxygen microbubbles |
| US8445546B2 (en) | 2006-10-25 | 2013-05-21 | Revalesio Corporation | Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures |
| WO2008115290A2 (en) | 2006-10-25 | 2008-09-25 | Revalesio Corporation | Methods of wound care and treatment |
| DK2119703T3 (da) | 2007-01-15 | 2013-01-14 | Santen Pharmaceutical Co Ltd | Nyt indolderivat med inhiberende virkning på I-B-kinase. |
| PE20081889A1 (es) | 2007-03-23 | 2009-03-05 | Smithkline Beecham Corp | Indol carboxamidas como inhibidores de ikk2 |
| US9745567B2 (en) | 2008-04-28 | 2017-08-29 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
| US9523090B2 (en) * | 2007-10-25 | 2016-12-20 | Revalesio Corporation | Compositions and methods for treating inflammation |
| US20100310609A1 (en) * | 2007-10-25 | 2010-12-09 | Revalesio Corporation | Compositions and methods for treatment of neurodegenerative diseases |
| US20100004189A1 (en) * | 2007-10-25 | 2010-01-07 | Revalesio Corporation | Compositions and methods for treating cystic fibrosis |
| US10125359B2 (en) | 2007-10-25 | 2018-11-13 | Revalesio Corporation | Compositions and methods for treating inflammation |
| US20100303871A1 (en) * | 2007-10-25 | 2010-12-02 | Revalesio Corporation | Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction |
| US20100008997A1 (en) * | 2007-10-25 | 2010-01-14 | Revalesio Corporation | Compositions and methods for treating asthma and other lung disorders |
| EP2285347A4 (en) | 2008-05-01 | 2011-09-21 | Revalesio Corp | COMPOSITIONS AND METHODS OF TREATING DISORDERS OF THE DIGESTION SYSTEM |
| EP2314575B1 (en) * | 2008-07-14 | 2013-06-19 | Santen Pharmaceutical Co., Ltd | Novel indole derivative having carbamoyl group, ureido group and substituted oxy group |
| US20100098687A1 (en) * | 2008-10-22 | 2010-04-22 | Revalesio Corporation | Compositions and methods for treating thymic stromal lymphopoietin (tslp)-mediated conditions |
| JP2012520257A (ja) | 2009-03-10 | 2012-09-06 | グラクソ グループ リミテッド | Ｉｋｋ２阻害剤としてのインドール誘導体 |
| US8815292B2 (en) | 2009-04-27 | 2014-08-26 | Revalesio Corporation | Compositions and methods for treating insulin resistance and diabetes mellitus |
| SG10201503600XA (en) | 2010-05-07 | 2015-06-29 | Revalesio Corp | Compositions and methods for enhancing physiological performance and recovery time |
| AU2011289172B2 (en) | 2010-08-12 | 2015-09-24 | Revalesio Corporation | Compositions and methods for treatment of taupathy |
| CN103561722A (zh) * | 2011-04-13 | 2014-02-05 | 利发利希奥公司 | 用于抑制和／或调整炎性神经变性疾病中涉及到的效应t细胞的组合物和方法 |
| US9707235B1 (en) * | 2012-01-13 | 2017-07-18 | University Of Kentucky Research Foundation | Protection of cells from degeneration and treatment of geographic atrophy |
| CN109438416B (zh) * | 2018-12-06 | 2020-04-10 | 河南师范大学 | 一种合成噻吩类抑制剂tpca-1的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0003154D0 (en) * | 2000-02-12 | 2000-04-05 | Astrazeneca Uk Ltd | Novel compounds |
| US6414013B1 (en) * | 2000-06-19 | 2002-07-02 | Pharmacia & Upjohn S.P.A. | Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention |
| AU2002211663A1 (en) * | 2000-10-12 | 2002-04-22 | Smith Kline Beecham Corporation | Nf-$g(k)b inhibitors |
| SE0102616D0 (sv) * | 2001-07-25 | 2001-07-25 | Astrazeneca Ab | Novel compounds |
| ES2315430T3 (es) * | 2001-10-04 | 2009-04-01 | Smithkline Beecham Corporation | Inhibidores de nf-kb. |
| WO2003029241A1 (en) * | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
-
2003
- 2003-12-05 US US10/537,697 patent/US20060116419A1/en not_active Abandoned
- 2003-12-05 EP EP03812858A patent/EP1569924A4/en not_active Withdrawn
- 2003-12-05 JP JP2004559435A patent/JP2006510676A/ja active Pending
- 2003-12-05 WO PCT/US2003/038970 patent/WO2004053087A2/en active Application Filing
- 2003-12-05 AU AU2003300832A patent/AU2003300832A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006510676A5 (pt-PT) | ||
| JP2005506334A5 (pt-PT) | ||
| JP2007522142A5 (pt-PT) | ||
| JP2005531584A5 (pt-PT) | ||
| JP2019038829A5 (pt-PT) | ||
| JP2018150331A5 (pt-PT) | ||
| DE69817393T2 (de) | Neue heterozyklische verbindungen | |
| CA2556463C (en) | Dihydropyridinone derivatives | |
| JP2008512458A5 (pt-PT) | ||
| RU2007102576A (ru) | Новые индаэолкарбоксамиды и их применение | |
| JP2007500720A5 (pt-PT) | ||
| JP2006514626A5 (pt-PT) | ||
| JP2004528295A5 (pt-PT) | ||
| JP2008510770A5 (pt-PT) | ||
| JP2005539045A5 (pt-PT) | ||
| JP2010539237A5 (pt-PT) | ||
| JP2013504613A5 (pt-PT) | ||
| JP2007529492A5 (pt-PT) | ||
| AU2020354138B2 (en) | Heteroarylamidopyridinol derivative and pharmaceutical composition comprising same as active ingredient for prevention or treatment of autoimmune disease | |
| JP2008512374A5 (pt-PT) | ||
| JP2019505532A5 (pt-PT) | ||
| JP2012502111A5 (pt-PT) | ||
| JP2014505107A (ja) | 過誤腫性腫瘍細胞を阻害する方法 | |
| JP2019501927A5 (pt-PT) | ||
| JP2509689B2 (ja) | セファロスポリン誘導体およびそれらの製法 |